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Summary In a study of chemotherapy as palliative treatment, 300 patients with untreated limited and
extensive stage small cell lung cancer (SCLC), who did not have progressive disease after the first cycle of
chemotherapy, were randomised to receive either regular 'planned' chemotherapy or chemotherapy given 'as
required' (AR). All patients received the same chemotherapy: cyclophosphamide 1 gmm-2 i.v., vincristine
2 mg i.v., and etoposide 120 mg m-2 i.v. on day 1, and etoposide 100 mg b.d. orally on days 2 and 3. Planned
chemotherapy was given regularly every 3 weeks. AR chemotherapy was given for tumour-related symptoms,
or for radiological progression of disease. Both groups of patients were assessed every 3 weeks and a
maximum of eight cycles of chemotherapy was given. A detailed quality of life assessment was made using
daily diary cards.
The median survival (MS) of patients given AR chemotherapy was not significantly worse than those
receiving planned treatment [MS: Planned = 36 weeks (95% C.I. 32-40 weeks), AR = 32 weeks (95% C.I.
28-37 weeks) P = 0.960]. In the AR patients the median interval between treatments was 42 days. On average
AR patients received half as much chemotherapy as planned patients. AR patients with a treatment-free
interval (TFI) of more than 8 weeks between the first and second cycles of chemotherapy survived longer than
those in whom this interval was less than 4 weeks; [MS: TFI >8 =47 weeks (95% C.I. 32-53 weeks); TFI
<4 = 24 weeks (95% C.I. 17-34 weeks) P = 0.013]. Contrary to expectation, in the quality of life assessment
the AR patients scored themselves as having more severe symptoms than patients receiving planned treatment.
AR chemotherapy is a novel method of attempting to use cytotoxic drugs palliatively, which resulted in less
drug treatment for approximately equivalent survival. However the palliative effect seen with as required
treatment was less satisfactory than with planned chemotherapy.
Small cell lung cancer (SCLC) is sensitive to both
chemotherapy and radiotherapy. Chemotherapy response
rates of greater than 80% are obtained in previously un-
treated patients (Klastersky et al., 1982; Aisner et al., 1986;
Feld et al., 1987; Smith et al., 1987; Jackson et al., 1988;
Spiro et al., 1989), and chemotherapy prolongs survival in
patients with both limited and extensive disease. Unfor-
tunately these high response rates do not result in significant
numbers of cures, and the overall 2-year survival is 5.9%,
with 3% alive at 7 years (Souhami & Law, 1990). Survival
beyond 2 years is largely confined to patients with limited
disease and good performance status who constitute only
25% of all cases (Osterlind & Andersen, 1986; Souhami &
Law, 1990). Chemotherapy relieves symptoms and increases
median survival even in patients who cannot be cured, but
these benefits have to be weighed against the toxicity and
inconvenience of treatment. In the course of a study designed
to assess the optimum duration of chemotherapy (Spiro et
al., 1989), a quality of life analysis suggested that symptoms
improved if chemotherapy was stopped early (Geddes et al.,
1990).
The present study was designed to assess two different
philosophies of treatment with cytotoxic drugs. In the first,
chemotherapy was used in the conventional manner, given in
regular planned cycles every 3 weeks. In the second,
chemotherapy was given only when the progression of the
disease or the development of symptoms dictated the need
for chemotherapy. A pilot study was first undertaken, and
the approach was feasible provided that the indications for
treating with chemotherapy were made clear. The two most
important end points of this study were therefore overall
survival and detailed assessment of quality of life. The
quality of life assessment was with daily diary cards as
described previously (Geddes et al., 1990).
Patients and methods
During the period February 1986 and September 1988, 300
patients with SCLC were entered into the study from the
participating hospitals. All patients had SCLC diagnosed by
histology (from bronchial biopsy, lymph node biopsy, or
biopsy, or biopsy of a metastasis), or by cytology either from
bronchial brushings at bronchoscopy or from two specimens
of sputum. Patients were under 76 years of age at the time of
diagnosis, and had no cardiac, renal or neurological disease
that would preclude the use of chemotherapy. All those
patients with SCLC presenting to the participating centres
who were judged to have a survival of more than 3 weeks
were entered into the study. There were no patients who
refused to be entered. Patients were excluded if they had been
treated for another malignant disease within the previous 3
years (except basal cell skin carcinoma), or if they had
received previous chemotherapy or radiotherapy for SCLC
(apart from those who received emergency radiotherapy for
superior vena vacal obstruction, or spinal cord compression).
Patients were staged by chest X-ray, full blood count, and
measurement of blood urea, electrolytes, liver function tests,
plasma proteins and calcium estimations, isotope bone scan
and liver ultrasound. Bone marrow examination was carried
out when indicated by an abnormal full blood count. Limited
disease (LD) was defined as disease confined to one hemi-
thorax or ipsilateral supraclavicular nodes. Extensive disease
(ED) was defined as more widespread local disease, or the
presence of metastases. Informed consent was obtained from
all patients according to the requirements specified by the
individual ethical committees of each of the participating
institutions.
Patients were randomised after diagnosis and staging. Ran-
domisation was either to receive planned chemotherapy every
3 weeks, or to receive chemotherapy on an 'as required' (AR)
basis. All patients received the first cycle of chemotherapy on
entry to the study but patients in either arm who had pro-
gressive disease at 3 weeks were taken off the protocol treat-
ment ('off study'). The comparison is therefore between the
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two treatment policies in those patients with stable or re-
sponding disease following the first cycle. Survival data are
presented both for all randomised patients and for those on
study following the first treatment. In both arms of the
study, the chemotherapy was cyclophosphamide 1 gm m2
i.v., vincristine 2mg i.v., and etoposide 120mgM2 m i.v., on
day 1, and etoposide 100 mg b.d. orally on days 2 and 3.
Each patient was reviewed every 3 weeks by clinical assess-
ment, chest radiograph, full blood count, urea, electrolytes
and liver function tests. A maximum of eight cycles of
chemotherapy was given. Protocol chemotherapy was discon-
tinued if there was progressive disease within 3 weeks of
previous chemotherapy or if there had been unacceptable
chemotherapy side effects. Treatment was given every 3
weeks in the planned group provided that the total white cell
count on the day of treatment was equal to or greater than
3.5 x 1O' I` and the platelet count was equal to or greater
than 100 x 109 I1-. If not, treatment dosage was reduced
according to the following schedule: if the total white cell
count was 3-3.5 x 1091-1, 75% of the cyclophosphamide
and of the intravenous etoposide was given, and if less than
3 x 1091, the treatment was not given and the blood count
was repeated a week later; if the platelet count was
75-100 x 1091-, cyclophosphamide and etoposide doeses
were reduced to 75%; any further decrease in platelet count
caused the treatment to be delayed and the blood count was
repeated a week later. These dose reductions were carried
over to subsequent treatment cycles. After the first course of
chemotherapy all patients had a blood count at 7-10 days. If
the total white cell count was <2 x 1091- patients were
treated prophylactically with Co-trimoxazole two tablets b.d.,
to avoid the high risk of treatment related mortality at 7-12
days following the first cycle in poor prognosis patients
(Morittu et al., 1989).
Patients receiving chemotherapy in the AR arm were
assessed every 3 weeks in the same way, but were not treated
unless it was 'required'. Treatment decisions were made ac-
cording to the guidelines in Table I. The same dose
modifications were made in the AR arm as in the planned
arm, although because treatment was usually given at inter-
vals greater than 3 weeks, chemotherapy was rarely delayed
as a result of myelosuppression.
Patients whose tumour progressed within 3 weeks of
previous chemotherapy were treated symptomatically includ-
ing the use of palliative radiotherapy but not further
chemotherapy. Patients whose tumours relapsed after
chemotherapy had been discontinued were also treated symp-
tomatically. Thoracic radiotherapy and prophylactic cranial
irradiation were not given as a part of the treatment proto-
col.
straight lines drawn across the tumour at right angles to each
other. Complete and partial responses had to be maintained
for at least 3 weeks (the time between two chemotherapy
cycles). Stable disease (SD) was either no change in the size
of the tumour, or any response that was less than 50%.
Progressive disease (PD) was recorded if the tumour in-
creased in size by more than 25%, or the patient developed a
new metastasis. Liver relapse was diagnosed with deteriorat-
ing liver function tests, and an abnormal isotope or ultra-
sound scan. If biochemical deterioration in liver function
tests occurred as an isolated feature, this was judged to be
due to metastatic disease if the abnormality was sustained or
increased at the next visit. Bone pain was interpreted as due
to metastatic disease if associated with either appropriate
X-ray changes or a positive bone scan. Relapse in lymph
node or skin lesions was confirmed by cytology or histology
only if there was doubt as to their nature. CNS relapse was
confirmed by CT brain scan, and carcinomatous meningitis
by examination of the CSF. Change in blood urea and
electrolytes possibly attributable to ectopic ADP production
was not interpreted as relapse if it occurred in insolation.
Statistical methods
In this study we were comparing a standard treatment with a
more conservative treatment. The hypothesis being tested was
that the two treatments would be similar in terms of survival,
but that the quality of life might be better for the AR
patients. The objective was the identification of the less toxic
treatment, provided it was not worse than the standard
treatment in terms of survival. The acceptable difference in
survival was agreed by the investigators at the start of the
study. With an expected 30% survival at 1 year, we wished to
be able to detect a > 15% difference in survival at 1 year.
Using the method of Makuch and Simon (1978) the total
number of patients required (ac = 0.10, P = 0.20 and a = 0.15)
was 230 (115 in each arm). Alternatively, statistical methods
using a one-tailed test (Freedman, 1982) indicated a total of
242 patients would be required when a = 5%, 1-P = 80%,
with an expected 30% 1 year survival, and the ability to
detect a 15% difference.
Patients were randomised centrally by the trial coordinator
using the sealed envelope method. The randomisations were
stratified according to treatment centre. Curves of survival
and treatment free interval were constructed according to the
method of Kaplan and Meier (1958) and statistical
significance estimated by the log-rank test (Peto et al., 1977).
Quality of life assessment
Response criteria
Response was assessed clinically, radiologically and
biochemically before each chemotherapy cycle. A complete
response (CR) was defined as complete radiological clearing
of the chest radiograph abnormality seen at diagnosis. All
symptoms and signs and biochemical abnormalities indicat-
ing metastatic disease should have resolved completely. Bron-
choscopic confirmation of complete response was not
required. A partial response (PR) was a 50% or greater
reduction in tumour area as measured by the sum of two
Table I Reasons for treating or not treating patients on 'as
required' chemotherapy
Reasons for treating Reasons for not treating
with chemotherapy with chemotherapy
Responding but symptomatic Responding and asymptomatic
SD and symptomatic SD and asymptomatic
PD but asymptomatic PD despite treatment
PD and symptomatic
PD = Progressive disease. SD = Stable disease.
A cohort of 62 patients taking part in the multi-institutional
randomised study also participated in the quality of life
assessment. The patients were treated in a single institution
(London Chest Hospital). They were under the care of a
single medical team and were judged to be capable of com-
plying with the diary card assessment. After diagnosis
patients were asked to participate in the study and gave
informed consent. All patients were aware of their diagnosis.
The nature of the trial was explained by one of two doctors.
The intention behind 'planned' and 'as required'
chemotherapy was explained in the same way to each patient.
Patients allocated to as required chemotherapy were told that
the progress of the disease would be closely monitored and
chemotherapy used as and when necessary. No patient
refused to take part.
The quality of life measure used was a diary card to be
completed daily by the patient (Figure 1). This card has been
compared by our group in a previous study (Geddes et al.,
1990) with the EORTC questionnaire, the Spitzer quality of
life index and the HAD scale and is a modification of the
card developed by the UK Medical Research Council
(Bleehen et al., 1989). The diary card was shown to be
sensitive to short term day to day changes in mood, and to568 H.M. EARL et al.
PLEASE ANSWER THE FOLLOWING QUESTIONS.
WRITE DOWN THE NUMBER OF YOUR ANSWER
WEEK 1
IN THE APPROPRIATE BOX OPPOSITE THIS PAGE Z7To7 Bd Th., F S., S .'
DID YOU FEEL SICK TODAY?
Not at all 2 Occasoonaliv
3 A lot 4 All the timeE
DID YOU VOMIT TODAY'
1 Nolat all 2 Once
3 Twice 4 More thaI Aw-Ce
HOOW GOOD HAS YOUR APPETITE BEEN TODAY'
1Good 2 Fa'
3; Poor 4 Bad
HOW MUCH PAIN HAVE YOU HAD TODAY'
None 2 A llttle
3 Ou-te a lot 4 A iot
HOW DID YOU SLEEP LAST NIGHT'
Verv well 2 OIPeweil
3 BadIly 4 Not at _
HOW HAPPY HAVE YOU BEEN TODAY'
HappV 2 Fa4IIV hadpy
3. Unhappy 4 Vefy unhappy_
HOW ARE YOU FEELING GENERALLY7
1. Well 2 Fa- 3.Poor 4 Verypoor
WHAT DID YOU DO TODAY'
Staved n bed 2 Got up - d,d nothing
3 Lght wtork/House work 4 Fully actve I
Figure 1 The daily diary card.
symptoms related to both the chemotherapy cycles and the
disease (Geddes et al., 1990). These findings have been
confirmed by Fayers et al. (in press). The nature of the diary
card was explained to the patient by a single research nurse
at the time of their first treatment. The patients were shown
how to complete it at the end of each day. The research
nurse checked the card at each visit and remained in contact
with the patient throughout the course of his or her illness.
The cards covered a 4 week period (to allow for treatment
delays) and were collected at each hospital or clinic visit,
when a new card was supplied. Eight questions were asked
and the patient responded by choosing the most appropriate
answer on a four point categorical scale according to the
severity of their symptoms. The questions were designed to
cover three areas: symptoms related mainly to treatment
sickness, vomiting, appetite; symptom related to disease -
pain; and a more general assessment - mood, sleep, activity
and general well being. Patients were encouraged to complete
the diary cards for as long as possible to enable a com-
parison of the two arms when those receiving planned
chemotherapy had completed eight courses and those on the
AR arm were still eligible for treatment. Results are ex-
pressed graphically as the proportion of the total weekly
scores for all patients which were scored as greater than
grade 1. We have previously shown (Geddes et al., 1990) that
this trend is identical (but the proportion lower) if the cut-off
point is taken as greater than 2 or 3. For comparison
between results in the diary card the Mann-Whitney non-
parametric test was used.
Results
Three hundred patients entered the study between February
1986 and September 1988, 155 to the planned arm and 145 to
the AR arm. After the first cycle of chemotherapy when the
patients were reassessed at 3 weeks, 23 patients (15%) from
the planned arm, and 25 patients (17%) from the AR arm
did not receive further chemotherapy on study and Table II
states the reasons. One hundred and thirty two patients in
the planned and 120 patients in the AR arm went on to
receive further treatment. Table III shows the patient charac-
teristics in the two arms of the study, both including and
excluding the patients who progressed after the first cycle.
Both groups were well matched for age, sex, performance
status (PS) and biochemical features. All 132 patients in the
planned arm of the study have completed their chemo-
therapy, whereas there are seven patients on the AR arm
who are still eligible to receive more chemotherapy at the
time of this analysis. At the present time these patients
remain in either complete or partial remission and are
Table II Reasons for treatment being discontinued after course
one
Planned As required
Progressive disease by Day 21 10 12
Death before Day 21 6 10
Patient withdrawal before Day 21 2 2
Diagnosis incorrect 3 -
Other 2 1
23 25
Table III Patient characteristics. Responding patients are patients who
did not have progressive disease after the first cycle
All patients Responding patients
Planned As required Planned As required
(155) (145) (132) (120)
Age
Range 39-75 43-75 39-75 43-75
Median 65 66 64 65
Stage
L 46 (29.7 %) 49 (33.8%) 41 (31.1%) 39 (32.5%)
E 109 (70.3%) 96 (66.2%) 91 (68.9%) 81 (67.5%)
Sex
M 119 (76.8%) 105 (72.4%) 102 (77.3%) 88 (73.3%)
F 36 (23.2%) 40 (27.6%) 30 (22.7%) 32 (26.7%)
PS
0 43 (27.7%) 44 (30.3%) 38 (28.8%) 42 (35%)
1 64 (41.3%) 50 (34.5%) 58 (43.9%) 44 (36.7%)
2 25 (16.2%) 25 (17.2%) 20 (15.2%) 20 (16.7%)
3 23 (14.8%) 26 (18%) 15 (11.4%) 14 (11.6%)
Plasma
Albumin' 89.66 89.41 89.66 91.11
Plasma
Naa 97.84 97.84 97.84 97.86
Alkaline
P'asel 97.06 105.88 97.14 104.00
'Values are median value of all patients expressed as % of the mean of
the normal range of each participating institution. L = Limited disease.
E = Extensive disease.CHEMOTHERAPY TRIAL FOR SCLC 569
asymptomatic from their disease. Four patients on the plan-
ned arm and seven patients on the AR arm withdrew from
treatment. Only one patient was lost to follow-up in the
study (AR arm).
The number of courses of chemotherapy received by the
patients is shown in Figure 2. 56.8% of patients on the
planned arm have received all eight courses ofchemotherapy,
compared with 12.4% of patients on the AR arm. The
median number of courses received by patients on the plan-
ned arm of the study was eight, compared with four for
patients on the AR arm. Dose reductions were infrequent. At
the 8th cycle the mean percentage intravenous dose was
91.7% in the planned arm and 95.8% in the as required. The
overall per cent dose per cycle was 91.7% in the planned and
96.6% in the as required treatment. In the planned arm
12.6% of cycles were delayed by 1 week.
Figure 3 shows the overall survival for all 300 patients
randomised. There was no significant difference in survival
between all patients randomised to receive planned or AR
chemotherapy, with median survivals of 35 weeks (95% C.I.
30-39 weeks) and 29 weeks (95% C.I. 25-33 weeks) respec-
tively (P = 0.464). There was no difference in overall survival
between the 252 patients who, with stable or responding
disease after the first cycle, received either planned or AR
chemotherapy, with median survivals of 36 (95% C.I. 32-40
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Figure 2 The number of courses received by all patients entered
onto study. E = AR chemotherapy, = Planned chemo-
therapy.
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weeks) and 32 (95% C.I. 28-37 weeks) weeks respectively
(Figure 4, P = 0.960). There was no difference in survival
between the two groups in patients with stable or responding
disease in the limited or extensive disease category (Figure 5a
and b).
The median interval between treatments in the AR arm
was 42 days. Figure 6 and the legend shows the method of
calculation and analysis of the treatment-free intervals
between each course. There are only minor changes in
median treatment free interval from course 1 through 8. It is
of note that approximately 10% of patients had treatment-
free intervals of 3 months or longer.
Figure 7 demonstrates overall survival by duration of first
treatment interval. Patients with a first treatment-free interval
of <4 weeks have a median survival of 24 weeks (95% C.I.
17-34 weeks); patients with an interval of 4-8 weeks have a
median survival of 33 weeks (95% C.I. 31-37 weeks); and
those with a first interval of > 8 weeks have a median
survival of 47 weeks (95% C.I. 32-53 weeks, trend test
P = 0.013).
Quality of life assessment
The characteristics of the patients studied in the quality of
life assessment and in the whole trial are compared in Table
IV. The study patients are representative of the trial as a
whole and the two arms are evenly matched. Table V shows
the number of patients studied during the period of
chemotherapy. During the period of observations patients
continued to fill in diary cards after relapse until they were
too ill to comply when they withdrew from the assessment.
This is the explanation of the diminution in numbers with
time. Table VI shows the numbers of patients treated for
each chemotherapy cycle. As in the whole study, patients on
the AR arm received approximately half the amount of
chemotherapy given to the patients on the planned pro-
gramme (106 cycles vs 196) before relapse within 3 weeks of
the last cycle. Patient compliance in return of completed
cards was excellent, with 438 out of a possible 506 (87%)
cards being returned (88% planned and 85% AR). Figure 8
shows the proportion of responses indicating nausea,
vomiting, depression of appetite and pain greater than grade
1 in both study groups. The peaks of nausea related to the
chemotherapy cycles in the planned arm are clearly demon-
strated. They are less apparent in the AR arm since
chemotherapy occurred at differing time intervals. In the
planned arm nausea diminished at week 22 when chemo-
therapy was discontinued. Nausea continues longer in the
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Figure 3 Overall survival for all randomised patients according
to randomisation. a, AR chemotherapy (n = 145, MS =29
weeks, 95% C.I. 25-33 weeks; observed deaths 134, expected
deaths 128). b, Planned chemotherapy (n = 155, MS = 35 weeks,
95% C.I. 30-39 weeks; observed deaths 141, expected deaths
147) P =0.464.
Time (Months)
Figure 4 Overall survival for all patients with stable or respond-
ing disease after the 1st cycle according to randomisation. A, AR
chemotherapy (n = 120, MS = 32 weeks, 95% C.I. 28-37 weeks;
observed deaths 112, expected deaths 112.) B, Planned chemo-
therapy (n = 132, MS = 36 weeks, 95% C.I. 32-40 weeks;
observed deaths 124, expected deaths 124), P = 0.960.
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Figure 7 Overall survival by duration of first treatment-free
interval, for AR chemotherapy patients only. a, first interval <4
weeks (n = 51, MS = 24 weeks, 95% C.I. 17-34 weeks). b, First
interval 4-8 weeks (n = 53, MS = 33 weeks, 95% C.I. 31-37
weeks). c, First interval >8 weeks (n = 43, MS = 47 weeks, 95%
C.I. 32-53 weeks). Trend Test P = 0.013.
Table IV Characteristics of the patients in the quality of life study
compared with all randomised patients with stable or responding
disease after the first cycle
Time (Months)
Figure 5 a: Overall survival for limited disease patients with
stable or responding disease after the first cycle according to
randomisation. A, AR chemotherapy (n = 39, MS =47 weeks,
95% C.I. 35-61 weeks; observed deaths 36, expected deaths 39).
B, Planned chemotherapy (n = 41, MS = 43 weeks, 95% C.I.
30-49 weeks; observed deaths 36, expected deaths 33); P = 0.495.
b: Overall survival for extensive disease patients with stable or
responding disease after the first cycle according to randomisa-
tion. A, AR chemotherapy (n = 81, MS= 28 weeks, 95% C.I.
23-32 weeks; observed deaths 76, expected deaths 71). B, Plan-
ned chemotherapy (n = 91, MS = 35 weeks, 95% C.I. 30-39
weeks; observed deaths 88, expected deaths 93), P = 0.464.
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Figure 6 Treatment-free interval curves for as required
chemotherapy patients only. The individual curves are not
identified since there is no difference between them. The curves
are constructed on the same principle as survival curves. A fall in
the curve indicates that a patient has received treatment, and the
points indicate that a patient has been treatment-free for that
length of time since their last treatment. The treatment-free inter-
vals pertain to those chemotherapy cycles before progression
through treatment occurs. The median treatment-free interval
(MTFI) between each course is as follows: Course interval 1-2
(n = 147, MTFI =43 days); Course 2-3 (n = 121, MTFI =42
days); Course 3-4 (n = 99; MTFI = 43 days); Course 4-5 (n = 72,
MTFI = 43 days; Course 5-6 (n = 55, MTFI = 41 days); Course
6-7 (n = 36, MTFI = 42 days); Course 7-8 (n = 20, MTFI = 41
days). Log Rank test P = 0.628. Trend Test P = 0.197.
Planned As required
Study Entire Study Entire
PS (%) group study group study
0 33.3 29.0 33.3 35.0
1 53.3 44.3 43.3 36.7
2 10.0 15.3 13.3 16.7
3 3.3 11.4 10.0 11.6
LD (%) 24.1 31.1 33.3 32.5
ED (%) 75.9 68.9 66.7 67.5
PS = Performance status. LD = Localised disease. ED = Extensive
disease.
Table V Numbers of patients returning cards during study
period
Week 1 4 8 12 16 20 24 28
Planned 32 29 27 26 23 21 17 17
As required 30 27 26 24 22 20 18 13
AR arm because chemotherapy continues longer. The impor-
tant observation is that there was no general reduction in the
level of nausea in the AR arm. Similar results (but for a
smaller proportion ofpatients) are obtained if grade 2 is used
as the cut-off point. These results are confirmatory of earlier
reports of the use of cards (Geddes et al., 1990). There are
more high scores for vomiting in the planned arm who are
receiving more chemotherapy cycles than AR patients, but
appetite shows a steady deterioration in the AR arm. Symp-
toms of pain were also more frequent in the AR group.
Figure 9 shows the results for sleep, mood, activity and
general well being. Disturbances of mood and sleep are more
frequent in the AR group. More of these patients also show
a deterioration in what we have described as 'general well
being'. Activity scores were slightly worse in the planned
group, possibly related to the greater number of hospital
admissions (note that activity is scored inversely, 100% being
all patients fully active).
Discussion
This study in patients with small cell lung cancer was
designed to answer a novel question in the use of cancer
chemotherapy. Does chemotherapy treatment given on an 'as
required' basis result in equivalent survival with a better
quality of life? Because the prognosis for SCLC remains very
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Table VI Numbers of patients treated at each chemotherapy cycle
Chemotherapy
cycle 1 2 3 4 5 6 7 8
Planned 32 29 27 26 23 21 21 17
(3weekly) 30 23 21 15 9 6 2 1
As required
Weekgiven: 7 (4-23) 13 (7-29) 19(10-37) 25 (14-48) 27(17-39)
median(range)
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Figure 8 The percentage ofweekly scores reporting symptoms of
grade 1 or more for nausea, vomiting, appetite, pain. There was
no significant difference in scores for vomiting (P = 0.30) but
nausea (P = <0.001), appetite (P = <0.001), pain (P = <0.001)
were more adversely affected in the AR group. * = AR group.
0 = Planned group.
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Figure 9 The percentage of weekly scores reporting symptoms of
grade 1 or more for sleep, mood, general well being and activity.
Mood (P =0.001, sleep (P = <0.001) and general well being
(P = <0.001) were adversely affected in the AR group. Activity
was worse (P = <0.05) in the planned group (note that activity
is scored in the opposite direction to the other symptoms
- a high
score indicating more activity). M = AR group. 0 = Planned
group.
poor, questions concerning the optimum use of chemo-
therapy for the aleviation of symptoms are of considerable
importance. The concept of 'as required' chemotherapy can
only ethically be adopted when the aims of the study are not
curative but palliative, since chemotherapy given 'as required'
is unlikely to be curative.
This study did not detect a significant worsening of sur-
vival as the result of the use of chemotherapy on an AR
basis. AR chemotherapy is therefore a feasible approach to
treatment in SCLC. Patients randomised to the planned arm
received on average twice as much chemotherapy as patients
treated on an AR basis. The treatment-free intervals in those
receiving AR chemotherapy remained relatively constant
throughout the course of treatment with a median of 6
weeks. The low overall median survivals for both limited and
extensive disease in this unselected group of patients is in
keeping with data from other large centres (Osterlind &
Andersen, 1986).
It is of interest that the regrowth interval of the tumour
appeared to have an association with prognosis. The longer
regrowth interval may be due either to a greater reduction in
tumour mass as a result of chemotherapy, or an intrinsically
slower growth rate. The fact that many patients with only a
partial response on X-ray showed a very slow regrowth of
the tumour suggests that the distribution of growth rates in
SCLC may be wider than is generaly assumed. Patients
whose tumour responded well to treatment and who had
long treatment-free intervals, had a better survival.
To assess quality of life we used the daily diary card which
we have shown gives detailed information on short-term
variations in symptoms which may not be detected by more
general questionnaires (Geddes et al., 1990). Compliance,
which is often a problem with self administered assessments
(Bleehen et al., 1989), was good, probably due to the fact
that the study was carried out in a single centre with a
research nurse assigned solely for this purpose. Patients in
both arms of the study continued to complete cards for as
long as possible. In the previous study (Geddes et al., 1990) a
decision was made to stop the assessment once progression
occurred. This was not appropriate when comparing planned
and as required chemotherapy, since in those randomised to
AR chemotherapy treatment was given only on disease pro-
gression or persistence of symptoms. However many patients
die in the first few months of treatment and only 30 of an
initial 62 patients were completing cards by week 28. Never-
theless almost 450 cards were collected, each containing at
least 160 scores and compliance in each group was very
similar.
The results confirm our previous report and that of Fayers
et al. (in press) that the diary card was sensitive enough to
detect the changing symptoms during treatment cycles and
also to show clear differences between the two treatment
policies. The diary card produces large amounts of repeated
data. In displaying and analysing the two groups the percent-
age of scores above (or below) a given level (1, 2, 3 or 4) was
calculated for each symptom category, for all patients, over a
period of 1 week. Although in theory it might be possible to
achieve the same results by collecting the data less frequently,
it was felt that the regularity of a daily recording was an
important factor in compliance. Following the suggestions of
Fayers and Jones (1983), who argue against over-sophisticated
analysis of the data, both the raw data and the weekly
proportions were compared using the Mann-Whitney non-
parametric test which confirmed the differences already evi-
dent in the graphical display shown in the figures. The results
are shown for scores greater than one. An identical trend was
observed if scores greater than two were taken. Too few
patients had scores greater than three or four for the analysis
to have value.
Giving chemotherapy on an AR basis proved to be a
successful way of reducing the number of treatments that
patients receive. The median treatment free interval was 6
weeks, resulting in AR patients receiving approximately half
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the number ofcourses as the planned patients. This reduction
in treatments did not lead to a significant survival difference
and resulted in one of the main side effects ofchemotherapy,
that of vomiting, being somewhat reduced. However in all
the other diary card measures excepting activity more AR
patients reported adverse symptoms.
Two possible explanations might account for the worse
quality of life in the AR group. Firstly it is possible that
patients felt that this treatment was a philosophy of failure,
and were distressed because they felt that they could not be
cured. This might have been reinforced each time
chemotherapy was given since at that time the disease might
be perceived as advancing. However there are arguments
against this interpretation. One team of two doctors
explained the study to patients who were then closely fol-
lowed by the research nurse. There were no adverse com-
ments about the trial reported by AR patients and neither
the nurse nor the doctors were aware of the trend towards
worse symptoms. In fact the treatment was very popular with
the medical staff and patients are likely to have perceived
this. The deterioration is therefore more likely to be due to
the physical effects of cancer which are alleviated by
chemotherapy even if at the expense of some toxicity. If this
interpretation is correct the study shows that, for most
patients, regular chemotherapy is an effective and useful
palliative treatment and that while patients dislike the side
effects of treatment, failure to control the effects of the
cancer diminishes quality of life to a greater degree.
Similar conclusions have been reached in the treatment of
metastatic breast cancer. Coates et al. (1987) conducted a
trial comparing planned, regular, chemotherapy administered
until progression of disease, with intermittent chemotherapy,
whereby treatment was stopped after 3 cycles and then
repeated for three more cycles only when there was evidence
of disease progression. Intermittent therapy in this group of
patients with metastatic breast cancer resulted in a
significantly worse response, a significantly shorter time to
disease progression, a trend towards shorter survival and was
associated with a worse quality of life than in patients treated
with regular, planned course of chemotherapy until disease
progression. It would therefore appear that chemotherapy
not only prolongs life but also improves its quality, an
inference also drawn by Tannock (1987) in reviewing the
study of Coates and co-workers (1987). This is an important
conclusion for all those involved in the treatment of patients
with SCLC and may also have relevance in the palliative
treatment of patients with metastatic disease from other
tumours that are responsive to chemotherapy. Finally, this
study illustrates the value of objective measurement when a
question of palliation is being asked and shows that the
perception of doctors and nurses may not accord with what
the patient experiences.
This study was supported by the Cancer Research Campaign. The
computing facilities were made available by the Imperial Cancer
Research Fund. Walter Gregory gave statistical advice and Mrs M.
Cohen typed the manuscript with great care. We would like to thank
the following for their referral or treatment of patients on this study:
Dr M. Apps, Dr R. Ashford, Dr L.R. Bagg, Dr R.A. Banks, Dr N.
Barnes, Dr D. Barrett, Dr K.M. Citron, Dr M. Cochrane, Dr P.
Cole, Dr J.V. Collins, Dr C. Coulter, Dr A.G. Davison, Dr N. Eiser,
Dr D.W. Empey, Dr R.W. Fowler, Dr D. Gamble, Dr J.R. Govan,
Dr M. Green, Dr M. Henk, Dr M.R. Hetzel, Dr M.E. Hodson, Dr
D. Hughes, Dr N. Johnson, Dr W.P. Kennedy, Dr R.K. Knight, Dr
V. Levison, Dr W.A.C. McAllister, Dr 0. McCarthy, Dr M.W.
McNicol, Dr J. Maher, Dr B.S. Mantell, Dr J. Meadway, Dr J.
Milledge, Dr D. Mitchell, Dr A. Newman-Taylor, Dr E.L. Offerman,
Dr W.R. Pratt, Dr J. Rees, Dr J. Riordan, Dr A. Rostrom, Dr M.
Smith, Dr P. Studdy, Dr D. Tong, Dr C. Trask, Dr J. Utting, Dr
S.G. Vaidya, Dr J. Waller, Dr J. Warren, Dr J. Wedzicha, Dr J.
Whittle, Dr R. Wilson, Dr J. Winter.
References
AISNER, J., WHITEACRE, M., ABRAMS, J. & PROPERT, K. (1986).
Doxorubicin, cyclophosphamide, etoposide and platinum, doxo-
rubicin, cyclophosphamide and etoposide for small cell carcinoma
of the lung. Seminiars in Oncol., 13 (Suppl 3), 54.
BLEEHEN, N.M., FAYERS, P.M., GIRLING, D.J. & STEPHENS, R.J.
(1989). Survival, adverse reactions and quality of life during
combination chemotherapy compared with selective treatment for
small cell lung cancer. Resp. Med., 83, 51.
COATES, A., GEBSKI, V., BISHOP, J.E. & 12 others (1987). Improving
the quality of life during chemotherapy for advanced breast
cancer. A comparison of intermittent and continuous treatment
strategies. New Engl J. Med., 317, 1490.
FAYERS, P.M. & JONES, D.R. (1983). Measuring and analysing
quality of life in cancer trials: a review. Stats. Med., 2, 429.
FAYERS, P.M., BLEEHEN, N.W., GIRLING, D.J. & STEPHENS, R.J. (in
press). Assessment of quality of life in small cell lung cancer
using a daily diary card developed by the Medical Research
Council Lung Cancer Working Party.
FELD, R., EVANS, W.K., COY, P. & 6 others (1987). Canadian multi-
center randomised trial comparing sequential and alternating
non-cross-resistant chemotherapy combinations in patients with
limited small cell carcinoma of the lung. J. Clin. Oncol., 5, 1401.
FREEDMAN, L. (1982). Tables of the number of patients required in
clinical trials using the log rank test. Stats. Med., 1, 121.
GEDDRES, D.M., DONES, L., HILL, E. & 5 others (1990). Quality of
life during chemotherapy for small cell lung cancer: use and
validation of a daily diary card in a randomised trial. Eur. J.
Cancer Clin. Oncol., 26, 484.
JACKSON, D.V., CASE, L.D., ZEKAN, P.J. & 13 others (1988). Im-
provement of long-term survival in extensive small cell lung
cancer. J. Clin. Oncol., 6, 1161.
KAPLAN, E.L. & MEIER, P. (1958). Non-parametric estimations from
incomplete observations. J. Am. Stat. Assoc., 53, 457.
KLASTERKSY, J., NICAISE, C., LONGVAL, E., STYCKMANS, P. &
THE EORTC LUNG CANCER WORKING PARTY. (1982). Cisplatin,
Adriamycin, and etoposide (CAV) for remission induction of
small cell bronchogenic carcinoma. Evaluation of efficacy and
toxicity and pilot study of a 'late intensification' with autologous
bone marrow rescue. Cancer, 50, 652.
MAKUCH, R. & SIMON, R. (1978). Sample size requirements for
evaluating a conservative therapy. Cancer Treat. Rep., 62, 1037.
MORITTU, L., EARL, H.M., SOUHAMI, R.L. & 5 others (1989).
Patients at risk of chemotherapy associated toxicity in small cell
lung cancer. Br. J. Cancer, 59, 801.
OSTERLIND, K. & ANDERSEN, P.K. (1986). A model for survival in
small cell lung cancer. A study of prognostic factors in 874
patients treated with chemotherapy with or without irradiation.
Cancer Res., 46, 4189.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomised clinical trials requiring prolonged observ-
ation of each patient. Br. J. Cancer, 35, 1.
SMITH, I.E., EVANS, B.D., GORE, M.E. & 4 others (1987). Carboplatin
(paraplatin; JM8) and etoposide (VP-16) as first-line combination
chemotherapy for small cell lung cancer. J. Clin. Oncol., 5, 185.
SOUHAMI, R.L. & LAW, K.S. (1990). Longevity in small cell lung
cancer. A report to the lung cancer subcommittee of the United
Kingdom Coordinating Committee for Cancer Research. Br. J.
Cancer, 61, 584.
SPIRO, S.G., SOUHAMI, R.L., GEDDES, D.M. & 6 others (1989). Dura-
tion of chemotherapy in small cell lung cancer. A Cancer
Research Campaign Trial. Br. J. Cancer, 59, 578.
TANNOCK, I.F. (1987). Treating the patient not just the cancer. New
Engi. J. Med., 317, 1534.